Author/Authors :
Rafinejad, Ali tehran university of medical sciences tums - Faculty of Pharmacy, Drug Design and Development Research Center - Department of Medicinal Chemistry, تهران, ايران , Fallah-Tafti, Asal tehran university of medical sciences tums - Faculty of Pharmacy, Drug Design and Development Research Center - Department of Medicinal Chemistry, تهران, ايران , Tiwari, Rakesh University of Rhode Island - College of Pharmacy - Department of Biomedical and Pharmaceutical Sciences, USA , Nasrolahi Shirazi, Amir University of Rhode Island - College of Pharmacy - Department of Biomedical and Pharmaceutical Sciences, USA , Mandal, Deendayal University of Rhode Island - College of Pharmacy - Department of Biomedical and Pharmaceutical Sciences, USA , Shafiee, Abbas tehran university of medical sciences tums - Faculty of Pharmacy, Drug Design and Development Research Center - Department of Medicinal Chemistry, تهران, ايران , Parang, Keykavous University of Rhode Island - College of Pharmacy - Department of Biomedical and Pharmaceutical Sciences, USA , Foroumadi, Alireza tehran university of medical sciences tums - Faculty of Pharmacy, Drug Design and Development Research Center - Department of Medicinal Chemistry, تهران, ايران , Akbarzadeh, Tahmineh tehran university of medical sciences tums - Faculty of Pharmacy, Drug Design and Development Research Center - Department of Medicinal Chemistry, تهران, ايران
Abstract :
Background: A series of 2-amino-4-aryl-4H-benzo[h or f]chromene-3-carbonitrile derivatives were synthesized and evaluated for inhibition of Src kinase and cell proliferation in breast carcinoma (BT-20) cell lines. Methods: The one-pot, three-component reaction of α or β-naphthol, malonitrile and an aromatic aldehyde in the presence of diammonium hydrogen phosphate was afforded the corresponding 2-amino-4-aryl-4H-benzo[h or f] chromene-3-carbonitrile derivatives, All target compounds were evaluated for inhibition of Src kinase and cell proliferation in breast carcinoma (BT-20) cell lines. Results: Among all tested compounds, unsubstituted 4-phenyl analog 4a showed Src kinas inhibitory effect with IC50 value of 28.1 μM and was the most potent compound in this series. In general, the compounds were moderately active against BT-20. 3-Nitro-phenyl 4e and 3-pyridinyl 4h derivatives inhibited the cell proliferation of BT-20 cells by 33% and 31.5%, respectively, and found to be more potent compared to doxorubicin (25% inhibition of cell growth). Conclusion: The data indicate that 4-aryl-4H-naphthopyrans scaffold has the potential to be optimized further for designing more potent Src kinase inhibitors and/or anticancer lead compounds.
Keywords :
Anticancer activity , Carbonitrile , Naphthopyrans , Protein kinase , Src kinase